

# Declaration of Interest

All PDVAC members have completed a declaration of interest form. Most interests were assessed as 'no conflict' of interest. In cases where a conflict of interest may be present (e.g. the PDVAC member's research institute has received a grant for a particular vaccine or candidate that is within PDVAC scope) members with relevant and significant interests recuse themselves for decisions on any related guidelines.

The following PDVAC members did not report any interests: Isabelle Bekerredjian-Ding, Sophie Biernaux, Marco Cavaleri, Hannah Clapham, Alejandro Cravioto, Mark Jit, Sonali Kochar (ex-officio member), Shaowei Li, Senjuti Saha, Kamel Senouci, Gerd Zettlmeissl.

The reported relevant interests are summarized below:

## **Ruth Karron, Chair**

- Consulted for Sanofi Pasteur in 2021 on RSV vaccines. This interest was perceived as personal, specific and financially insignificant.\*
- Prof. Karron is a chair at Johns Hopkins School of Public Health, which received a research grant from Sanofi Pasteur in 2022 for research on a live attenuated paediatric RSV candidate vaccine, this was assessed as non-personal, specific, and financially significant.\* Should guidelines be developed for such a vaccine and reviewed by PDVAC, Prof. Karron will recuse herself from decision making.

## **Raman Rao, Vice Chair**

- Dr Rao is the Chief Executive Officer of Hilleman Laboratories, which is a joint venture between Wellcome Trust and Merck. Hilleman Laboratories is a not-for-profit organization that has a public health mission to develop affordable vaccines and biologics against infectious diseases prevalent in LMICs, including through technology transfer and capacity building. This is very well aligned with the mission of PDVAC. Hilleman laboratories is an independent organization with no operational support from either Merck or Wellcome Trust. However, recognizing the affiliation of Hilleman Laboratories with Merck, and the *perception* of potential conflict, Dr Rao will recuse himself from decision making on the development of guidelines related to vaccine candidates where Merck has an interest.

## **Kwaku Poku Asante (ex-officio member)**

- Dr Asante has received funds as a principal investigator to his institute for the RTS,S malaria vaccine however this is not within PDVAC scope as it is a licensed vaccine with a SAGE policy recommendation.

## **Sinead Delany-Moretlwe**

- Her research institute receives funds from GSK as a trial site for gonococcal vaccine. This was assessed as non-personal, specific, and financially significant.\* Should any guidelines be developed for this type of vaccine and reviewed by PDVAC, Dr Delany-Moretlwe will recuse herself from decision making.

### **Willem Hanekom**

- Dr Hanekom's research institute is a site for TB vaccine trials, and he serves as a principal investigator. This was assessed as non-personal, specific, and financially significant.\* Should any guidelines be developed for this type of vaccine and reviewed by PDVAC, he will recuse herself from decision making.

### **Ghassan Dbaibo**

- Dr Dbaibo, receives honoraria for serving as an advisor for pharmaceutical companies, this was assessed as personal, non-specific, and financially insignificant. In addition, his institute receives research grants from pharmaceutical companies, this was assessed as non-personal, non-specific, and financially significant.\* This is not related to vaccines in PDVAC scope.

### **William Hausdorff**

- He is a co-inventor of various pneumococcal vaccine technologies but receives no royalties. This was assessed as non-specific and not significant.\* Pneumococcal vaccines are not within PDVAC scope.

### **Faith Osier**

- Prof Osier's institute received research grants for malaria research, related to immunological mechanisms. This was assessed as specific, significant and non-personal. Since the research grants are not related to or relevant to a particular vaccine candidate, they were not considered a conflict of interest.

### **Mariagrazia Pizza**

- Prof Pizza was employed by GSK until 2022. This relationship has now ceased.
- She owns shares in GSK. For decision making on guidelines related to vaccine candidates where GSK has an interest, she will recuse herself.

### **Marian Wentworth**

- Until March 2024, Marian served on the board of PharmaJet, in addition she is the holder of restricted stock on PharmaJet. This was assessed as personal, non-specific and significant.\* PharmaJet is not being reviewed by PDVAC currently.

\* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine

manufacturer or other vaccine-related company exceeds 5,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”.